Treating acute and chronic inflammatory diseases by blocking interleukin-1 beta (IL-12) activity is now part of clinical practice. There are 11 members of the IL-1 family and most induce inflammation. The function of one member, IL-1 family member 7 (IL-1F7), remains elusive. Since its discovery in 2000, there are only 9 papers. Of all members of the IL-1 family, IL-1F7 and IL-18 are the most closely related at the genomic level. There is one report that caspase-1 cleaves the recombinant IL-1F7 precursor and that processed IL-1F7 binds to the IL-18 receptor. However, there is no convincing data that recombinant IL-1F7 exhibits either pro- or anti- inflammatory activities. To avoid difficulties with recombinant forms, we transfected the IL-1F7 precursor into mouse and human cells and observed a profound suppression of endotoxin- and IL-12-induced pro- inflammatory cytokines. Silencing of endogenous IL-1F7 results in higher levels of pro-inflammatory cytokines. Importantly, IL-1F7 translocates to the nucleus. Thus, similar to IL-11 and IL-33, IL-1F7 appears to be a "dual function" cytokine, that is, functional in the nucleus as well as binding to a cell surface receptor. One hypothesis being tested is whether IL-1F7 binds to the IL-18 receptor and whether such a complex recruits the inhibitory receptor, Single Ig IL-1 Related Receptor (SIGIRR) to suppress cytokines. Another hypothesis being tested is whether the nuclear function of IL-1F7 requires Smad3, the intracellular protein that mediates TGF2 signaling. In addition to testing these hypotheses in cell cultures, we have generated a strain of mice that express human IL-1F7. IL-1F7 transgenic mice are significantly protected against the systemic and local inflammation of endotoxin, dextran sodium sulfate colitis, acute myocardial ischemic infarction and contact antigen sensitization. IL-1F7 now emerges as a major inhibitory cytokine that limits inflammation during innate immune responses. We propose to use these mice to test each of the hypotheses by creating three new strains of mice, each expressing IL-1F7 but deficient in either the IL-18 receptor, SIGIRR or Smad3. The goal of this proposal is to reveal the molecular requirements for the anti-inflammatory activity of IL-1F7. IL-1F7 appears to fill a gap in understanding how the innate immune response is regulated.

Public Health Relevance

The relevance of the project is one of human disease in which inflammation plays an important component. Much of inflammation is triggered by small protein molecules called cytokines that act to stimulate genes that cause inflammation. The project seeks to understand how inflammation caused by cytokines is controlled. This information will result in a better understanding of disease severity and possibly new anti-inflammatory therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI015614-34
Application #
8451338
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Dong, Gang
Project Start
1986-12-01
Project End
2015-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
34
Fiscal Year
2013
Total Cost
$343,275
Indirect Cost
$110,625
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Luo, Yuchun; Cai, Xiangna; Liu, Sucai et al. (2014) Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A 111:15178-83
Dinarello, Charles Anthony (2014) Interleukin-1? neutralisation in patients with cancer. Lancet Oncol 15:552-3
Bulau, Ana-Maria; Nold, Marcel F; Li, Suzhao et al. (2014) Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci U S A 111:2650-5
Van Tassell, Benjamin Wallace; Arena, Ross; Biondi-Zoccai, Giuseppe et al. (2014) Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113:321-7
van der Meer, Jos W M; Simon, Anna; Dinarello, Charles A (2014) Comment on "Power of rare diseases: found in translation". Sci Transl Med 6:219le1
Marcondes, A Mario; Karoopongse, Ekapun; Lesnikova, Marina et al. (2014) ?-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood 124:2881-91
Nold-Petry, Claudia A; Rudloff, Ina; Baumer, Yvonne et al. (2014) IL-32 promotes angiogenesis. J Immunol 192:589-602
Christensen, Dan Ploug; Gysemans, Conny; Lundh, Morten et al. (2014) Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and ?-cell protection. Proc Natl Acad Sci U S A 111:1055-9
Choi, Sung Won; Braun, Thomas; Chang, Lawrence et al. (2014) Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 15:87-95
Falcao, Raquel Appa; Christopher, Sanah; Oddi, Claudia et al. (2014) Interleukin-10 in patients with ST-segment elevation myocardial infarction. Int J Cardiol 172:e6-8

Showing the most recent 10 out of 506 publications